A carregar...
Neoadjuvant Therapy with Weekly Nanoparticle Albumin‐Bound Paclitaxel for Luminal Early Breast Cancer Patients: Results from the NABRAX Study (GEICAM/2011‐02), a Multicenter, Non‐Randomized, Phase II Trial, with a Companion Biomarker Analysis
BACKGROUND. Nanoparticle albumin‐bound paclitaxel (nab‐Paclitaxel) is an alternative to standard taxanes for breast cancer (BC) treatment. We evaluated nab‐Paclitaxel efficacy as neoadjuvant treatment for early estrogen receptor‐positive (ER+), human epidermal growth factor receptor 2‐negative (HER2...
Na minha lista:
| Publicado no: | Oncologist |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
AlphaMed Press
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5679821/ https://ncbi.nlm.nih.gov/pubmed/28701571 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2017-0052 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|